InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)
SIM0004
ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
Product group Antibodies
Overview
- SupplierBio X Cell
- Product NameInVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)
- Delivery Days Customer7
- ApplicationsFlow Cytometry, Western Blot, ELISA, Neutralisation/Blocking
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDIpilimumab
- Concentration4-11 mg/ml
- Estimated Purity>95%
- HostHuman
- IsotypeIgG1
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- Watanabe T, Ishino T, Ueda Y, et al. Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 2023,114(5):1859-1870. doi: 10.1111/cas.15756Read this paper
- Crupi MJF, Taha Z, Janssen TJA, et al. Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer. Front Immunol. 2022,13:1029269. doi: 10.3389/fimmu.2022.1029269Read this paper
- Qiu H, Zmina PM, Huang AY, et al. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties. Cancer Lett. 2018,434:144-151. doi: 10.1016/j.canlet.2018.07.024Read this paper
